Sulindac - CAS 38194-50-2
Catalog number: 38194-50-2
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C20H17FO3S
Molecular Weight:
356.41
COA:
Inquire
Targets:
COX
Description:
Sulindac is a non-steroidal COX inhibitor, which potently inhibits prostaglandin synthesis, used in the treatment of acute or chronic inflammatory conditions.
Purity:
>98%
Synonyms:
MK-231; MK231; MK 231; Sulindac; Aflodac; Algocetil
MSDS:
Inquire
InChIKey:
MLKXDPUZXIRXEP-MFOYZWKCSA-N
InChI:
InChI=1S/C20H17FO3S/c1-12-17(9-13-3-6-15(7-4-13)25(2)24)16-8-5-14(21)10-19(16)18(12)11-20(22)23/h3-10H,11H2,1-2H3,(H,22,23)/b17-9-
Canonical SMILES:
CC1=C(C2=C(C1=CC3=CC=C(C=C3)S(=O)C)C=CC(=C2)F)CC(=O)O
1.New use for an Old drug: COX-independent anti-inflammatory effects of sulindac in CF models.
Rocca J1,2, Manin S1, Hulin A3, Aissat A1,2,3, Verbecq-Morlot W2, Prulière-Escabasse V1,2,4, Wohlhuter-Haddad A1,5, Epaud R1,2, Fanen P1,2,3, Tarze A1,2. Br J Pharmacol. 2016 Feb 19. doi: 10.1111/bph.13464. [Epub ahead of print]
BACKGROUND AND PURPOSE: Pulmonary disease is the main cause of morbidity and mortality in cystic fibrosis (CF) patients due to exacerbated inflammation. To date, the only anti-inflammatory drug available to CF patients is high-dose ibuprofen, which can slow pulmonary disease progression, but whose cyclooxygenase-dependent digestive adverse effects limit its clinical use. Our aim is to test sulindac, another non-steroidal anti-inflammatory drug having a yet undefined anti-inflammatory effect in CF airway epithelial cells.
2.[Clinical and molecular characteristics of a child with familial adenomatous polyposis].
Zhang J1, Li ZL, Huang XB, Ye JX. Zhonghua Er Ke Za Zhi. 2016 Mar;54(3):205-8. doi: 10.3760/cma.j.issn.0578-1310.2016.03.010.
OBJECTIVE: To explore the clinical features and molecular mutation of early-onset familial adenomatous polyposis(FAP) in childhood.
3.Wnt/β-catenin pathway in the prefrontal cortex is required for cocaine-induced neuroadaptations.
Cuesta S1,2,3, Severin MJ3, Batuecas J3, Rosso SB1,3, Pacchioni AM1,3. Addict Biol. 2016 Feb 22. doi: 10.1111/adb.12377. [Epub ahead of print]
Behavioral sensitization is a progressive and enduring enhancement of the motor stimulant effects elicited by repeated administration of drugs of abuse. It can be divided into two distinct temporal and anatomical domains, termed initiation and expression, which are characterized by specific molecular and neurochemical changes. This study examines the role of the Wnt canonical pathway mediating the induction of cocaine sensitization. We found that β-catenin levels in the prefrontal cortex (PFC), amygdala (Amyg) and dorsal striatum (CPu) are decreased in animals that show sensitization. Accordingly, GSK3β activity levels are increased in the same areas. Moreover, β-catenin levels in nuclear fraction, mRNA expression of Axin2 and Wnt7b are decreased in the PFC of sensitized animals. Then, in order to demonstrate that changes in the PFC are crucial for initiation of sensitization, we either rescue β-catenin levels with a systemic treatment of a GSK3β inhibitor (Lithium Chloride) or inhibit Wnt/β-catenin pathway with an intracerebral infusion of Sulindac before each cocaine injection.
4.Effect of Sulindac and Erlotinib vs Placebo on Duodenal Neoplasia in Familial Adenomatous Polyposis: A Randomized Clinical Trial.
Samadder NJ1, Neklason DW2, Boucher KM3, Byrne KR4, Kanth P4, Samowitz W5, Jones D6, Tavtigian SV6, Done MW7, Berry T7, Jasperson K7, Pappas L7, Smith L7, Sample D7, Davis R7, Topham MK8, Lynch P9, Strait E10, McKinnon W11, Burt RW12, Kuwada SK13. JAMA. 2016 Mar 22-29;315(12):1266-75. doi: 10.1001/jama.2016.2522.
IMPORTANCE: Patients with familial adenomatous polyposis (FAP) are at markedly increased risk for duodenal polyps and cancer. Surgical and endoscopic management of duodenal neoplasia is difficult and chemoprevention has not been successful.
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related COX Products


CAS 530-78-9 Flufenamic acid

Flufenamic acid
(CAS: 530-78-9)

Flufenamic Acid is an anti-inflammatory agent, and also acts as an ion channel modulator.

CAS 202409-33-4 Etoricoxib

Etoricoxib
(CAS: 202409-33-4)

A selective COX-2 inhibitor

FR-188582
(CAS: 189699-82-9)

FR-188582, with anti-inflammatory and ulcerogenic properties, is a highly selective inhibitor of COX-2 with IC50= 0.017 microM.

CAS 53-86-1 Indomethacin

Indomethacin
(CAS: 53-86-1)

A nonselective COX1 and COX2 inhibitor with IC50 of 0.1 μg/mL and 5 μg/mL, respectively

CAS 169590-42-5 Celecoxib

Celecoxib
(CAS: 169590-42-5)

A highly selective COX-2 inhibitor

CAS 180200-68-4 JTE522

JTE522
(CAS: 180200-68-4)

JTE522, a selective COX-2 inhibitor, can induce apoptosis and inhibit cell proliferation in human endometrial cancer cell line RL95-2 cells and to explore the m...

CAS 61618-27-7 Amfenac sodium monohydrate

Amfenac sodium monohydrate
(CAS: 61618-27-7)

Amfenac is a COX inhibitor with IC50 of 0.25 and 0.15 μM for COX-1 and COX-2, respectively.

CAS 68767-14-6 Loxoprofen

Loxoprofen
(CAS: 68767-14-6)

Loxoprofen is a non-steroidal anti-inflammatory drug in the propionic acid derivatives group, which also includes ibuprofen and naproxen among others. It is a n...

Chemical Structure

CAS 38194-50-2 Sulindac

Quick Inquiry

Verification code

Featured Items